NCB：癌症治疗导致PI3激酶抑制剂抗药性机制
2012-01-22 MedSci MedSci原创
近日，国际著名杂志《自然—化学生物学》Nature Chemical Biology上刊登了维也纳研究人员的最新研究成果“A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer，”，文章中，研究人员发现了癌症治疗中导致PI3激酶（PI3K）抑制剂抗药性的机制，将有助于科学家们在
近日，国际著名杂志《自然—化学生物学》Nature Chemical Biology上刊登了维也纳研究人员的最新研究成果“A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer，”，文章中，研究人员发现了癌症治疗中导致PI3激酶（PI3K）抑制剂抗药性的机制，将有助于科学家们在这种抗药性出现之前开发出对付它的新战略，同时提高患者的治疗效果。
在超过25%的乳腺癌患者体内，负责编码PI3K的基因发生了变异，促进了乳腺恶性肿瘤的生长。PI3K抑制剂的开发已经到了临床试验阶段，然而，尽管这种治疗方法充满前景，但针对目标治疗的抗药性经常出现。
Sebastian Nijman和同事用一种化学遗传学方法，预料乳腺癌细胞中NOTCH1通道和c-MYC基因的活性能对PI3K抑制剂形成抗性。以前的研究并没有将NOTCH1通道与乳腺癌联系在一起。作者相信，通过认识治疗过程中肿瘤上所发生的变化类型，科学家们能够在PI3K抑制剂抗药性形成之前开发更好的方法来对付它。（生物谷Bioon.com）
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
Markus K Muellner, Iris Z Uras, Bianca V Gapp, Claudia Kerzendorfer, Michal Smida, Hannelore Lechtermann, Nils Craig-Mueller, Jacques Colinge, Gerhard Duernberger & Sebastian M B Nijman
Linking the molecular aberrations of cancer to drug responses could guide treatment choice and identify new therapeutic applications. However, there has been no systematic approach for analyzing gene-drug interactions in human cells. Here we establish a multiplexed assay to study the cellular fitness of a panel of engineered isogenic cancer cells in response to a collection of drugs, enabling the systematic analysis of thousands of gene-drug interactions. Applying this approach to breast cancer revealed various synthetic-lethal interactions and drug-resistance mechanisms, some of which were known, thereby validating the method. NOTCH pathway activation, which occurs frequently in breast cancer, unexpectedly conferred resistance to phosphoinositide 3-kinase (PI3K) inhibitors, which are currently undergoing clinical trials in breast cancer patients. NOTCH1 and downstream induction of c-MYC over-rode the dependency of cells on the PI3K-mTOR pathway for proliferation. These data reveal a new mechanism of resistance to PI3K inhibitors with direct clinical implications.
作者：MedSci
版权声明：
本网站所有注明“来源：梅斯医学”或“来源：MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明“来源：梅斯医学”。其它来源的文章系转载文章，本网所有转载文章系出于传递更多信息之目的，转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#癌症治疗#
0
#激酶抑制剂#
37
#抗药性#
37
#激酶#
35
#抑制剂#
33